Allarity Therapeutics, Inc. Net Income (Loss) Attributable to Parent, Diluted
Allarity Therapeutics, Inc. (ALLR) reported Net Income (Loss) Attributable to Parent, Diluted of -$17.58 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2023-03-13
- Allarity Therapeutics, Inc. net income (loss) attributable to parent, diluted for fiscal 2022 was -$17.58M.
- Allarity Therapeutics, Inc. net income (loss) attributable to parent, diluted for fiscal 2021 was -$26.52M.
- Allarity Therapeutics, Inc. net income (loss) attributable to parent, diluted for fiscal 2020 was -$6.42M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|
| 2022-12-31 | -$17.58M 10-K · filed 2023-03-13 |
| 2021-12-31 | -$26.52M 10-K · filed 2023-03-13 |
| 2020-12-31 | -$6.42M 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |